Trial Profile
A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic Alterations
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Erdafitinib (Primary) ; Metformin; Midazolam
- Indications Carcinoma; Urogenital cancer
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 05 Jul 2023 This trial has been completed in Belgium (End Date: 13 Jun 2023), according to European Clinical Trials Database record.
- 03 May 2023 Planned End Date changed from 1 Dec 2023 to 29 Dec 2023.
- 12 Apr 2023 Planned End Date changed from 31 Mar 2023 to 1 Dec 2023.